Quick Answer
Edgewise Therapeutics, Inc. reported Total Assets of $552.60 million for the year ending 2025.
- Edgewise Therapeutics, Inc. showed an increase of +13.5% in Total Assets from 2024 to 2025.
- This data is from Edgewise Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $311.25 million | Q2 2021: $303.49 million | Q3 2021: $294.45 million | Q1 2022: $272.75 million | Q2 2022: $257.40 million | Q3 2022: $377.15 million | Q1 2023: $346.40 million | Q2 2023: $330.63 million | Q3 2023: $311.36 million | Q1 2024: $553.81 million | Q2 2024: $531.65 million | Q3 2024: $511.28 million | Q1 2025: $454.39 million | Q2 2025: $613.33 million | Q3 2025: $583.47 million.
- Over the full 6 years of available data (2020 to 2025), Edgewise Therapeutics, Inc.'s Total Assets has grown by 321.4%.
- Historical annual values: Fiscal year 2025: $552.60 million | Fiscal year 2024: $486.82 million | Fiscal year 2023: $340.04 million | Fiscal year 2022: $367.10 million | Fiscal year 2021: $285.23 million | Fiscal year 2020: $131.14 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: